Neovascular Glaucoma Treated With Ahmed Valve Implantation And Ranibizumab
Published 2026 - 44th Congress of the ESCRS
Reference: PP27.10 | Type: Free paper | DOI: 10.82333/8qmt-pm54
Authors: Dr Aliki Panagiotis Liaska* 1 , Mrs Efstathia Griva 1 , Dr Aikaterini PAPANAGNOU 1 , Mrs Styliani Stamelou 1
1Department of Ophthalmology,General Hospital of Lamia,Lamia,Greece
Purpose
to present long term results of ranibizumab treatment in eyes with neovascular glaucoma already treated with combined cataract surgery and Ahmed valve implantation
Setting
Department of Ophthalmology, General Hospital of Lamia, Lamia, GREECE
Methods
case series of 2 male patients (3 eyes) with neovascular glaucoma (NVG) and cataract. Patient 1, age 70 , diabetic NVG, Patient 2 , age 65, NVG in both eyes after Branch Retinal Artery Occlusion. Initial IOPs were 38, 50 and 25 mmHg, respectively. All eyes had combined Ahmed valve implantation and cataract surgery (phaco and three pieces intraocular lens (IOL) ) and subsequently Ranibizumab (Lucentis) injections approximately every 3 months. Follow up was 6, 24 and 36 months respectively.
Results
Intraocular pressure remained below 21mmHg with topical medications during the follow up period and visual acuity was stable. IOL remained well positioned. However, all patients presented temporary IOP rise in case of exacerbation of neovascularization. Treatment with ranibizumab restored hypertonia.
Conclusions
the combination of Ahmed valve implantation, cataract surgery and antiVEGF injection on a PRN scheme (approximately every 3 months) provides a reliable treatment regimen for neovascular glaucoma. Closed follow up and patient consultation is necessary for the successful treatment of these patients.